The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access ...
Biogen Inc (BIIB) stock reached a 52-week high of 177.37 USD, marking a significant milestone for the biotechnology company. This peak reflects an 11.02% increase in its stock price over the past year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback